Paracetamol oral use, immediate release formulations product-specific bioequivalence guidance

  • Email
  • Help
Current effective version

Adopted guideline

Adopted guideline enters into effect 01/08/2018 - see below

Reference numberEMA/CHMP/356877/2017
Effective from01/08/2018
KeywordsBioequivalence, generics, paracetamol
DescriptionThis document provides product-specific guidance on the demonstration of the bioequivalence of paracetamol.
  • BCS Classification: Biopharmaceutics Classification System
  • AUC0-t: area under the plasma concentration curve from administration to last observed concentration at time t
  • Cmax: maximum plasma concentration

Document history

First version

Current version

Adopted guideline



Overview of comments



Draft guideline

Published: 01/02/2018
Effective from: 01/08/2018


Published: 01/02/2018



Published: 28/07/2017

Related content

How helpful is this page?

Average rating:

 Based on 16 ratings

Add your rating:

See all ratings
3 ratings
3 ratings
3 ratings
3 ratings
4 ratings

Tell us more